智通财经网·2025-11-06 11:13Core Viewpoint - ST Unimed (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, to conduct a Phase III clinical trial for its innovative drug, recombinant human nerve growth factor SMR001 eye drops, aimed at treating moderate to severe dry eye syndrome [1] Summary by Categories Company Developments - The ethical approval for the Phase III clinical trial signifies that the project has met the necessary ethical compliance requirements to proceed [1] - The initiation of this clinical trial is not expected to have a significant impact on the company's operating performance in the short term [1]